Tumor resection followed by reconstruction with a proximal femoral endoprosthesis or an allograft-prosthesis composite are the two main alternatives for treatment of proximal femoral malignancies. This review describes the revision rate, implant survival, limb salvage rate, and function. Overall revision rates are high and reasons for failure differ between treatment modalities. Rate and reasons for amputation are comparable between both methods. Functional outcome was reasonable to good on average for both treatment modalities. Level of evidence: IV, systematic review and meta-analysis.
predefined criteria. We included studies that reported on one or more of the following outcomes: revision rate, reason for revision, implant survival, limb salvage rate, and functional outcome after endoprosthetic reconstruction of proximal femoral tumors.
Modular and custom endoprosthetic reconstructions (tumor prostheses) and allograft-prosthesis composite reconstructions after proximal femur resection are considered. All tumor typesmalignant, benign, secondary (ie, bone metastases), hematological malignancy-are included as outcomes were only occasionally reported separately per tumor type. We did not apply an age limit.
We excluded: case reports, studies with less than 10 cases per treatment modality, proximal femoral replacements for other reasons than tumor (eg, trauma), growing or expandable prosthesis, total femoral replacements, autograft-prosthesis composites, papers that do not present original data (eg, review articles, technique papers, letters to the editor), meeting abstracts, studies with mixed cohorts (eg, multiple anatomical regions, different types of reconstructions) without clear subgroup reporting, and studies published in a language other than English. We did allow for the inclusion of revision procedures (only for tumor), and for acetabular cup placement/reconstructions as long as the proximal femur was the primarily affected region. In case of overlapping cohorts, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] we included the most comprehensive, largest, or most recent cohort. 7, 8, [10] [11] [12] 16 All references of included studies were screened for publications missed by our search and no new eligible studies have been identified.
Two reviewers (blinded initials) appraised the quality of the included studies using predefined criteria based on the MINORS (methodological index for non-randomized studies) instrument and extracted data using a standardized sheet. 17 Any discordant F I G U R E 1 Flowchart demonstrating number of papers identified and article selection using predefined eligibility criteria. APC, allograftprosthesis composite; TP, tumor prosthesis. References of included studies were checked for publications missed by our search and no new eligible studies have been identified. See Section 2 for detailed description of article selection and eligibility criteria judgments in article selection, quality appraisal, and data extraction was resolved by consensus discussion.
| Outcome measures
The following outcome measures were collected from included studies per treatment modality (tumor prosthesis and allograft- We defined limb salvage rate as the proportion of patients that did not undergo amputation during the study period. We categorized reasons for amputation into infection, tumor recurrence/progression, and instability.
We reported the Musculoskeletal Tumor Society (MSTS) score to assess functional outcome as it was most commonly reported (23 studies reported the MSTS score). Only two studies reported the Toronto Extremity Salvage score, 8, 19 and six studies reported the Harris Hip score. 11, [20] [21] [22] [23] [24] The MSTS score is a clinician completed assessment rating six domains, resulting in a score of 0 to 100%, with a higher score indicating better function. 25 We collected the following study characteristics: reconstruction type, 
| Statistical analysis
We narratively reported results because of heterogeneity and sensitivity to bias. Revision rate, reasons for revision, implant survival, and limb salvage rate are reported as proportions to the included patients per treatment modality per study and overall. MSTS score is reported as a percentage per treatment modality per study. 
| Study characteristics

| Patient characteristics
Thirty-three studies reported on 1701 reconstructions with a tumor prosthesis in 1697 patients. The average age of patients who had a tumor prosthesis ranged from 26 to 71 years, and 51% were men 58 (67) 6 (7) 19 (22) 3 ( (25) 5 (5) 65 (65) 5 ( (60) 3 (6) 18 ( 25 (40) 5 (8) 32 ( (55) 2 (18) 2 (18) 1 (9) Gao et al (45) 11 (25) 5 (11) 8 (18) Ogilvie et al (range among studies: 30% to 76%) ( Overall revision rate ranged from 0% to 69% in tumor prostheses (overall: 10%) ( Table 2) . Reasons for implant failure after reconstruction with a tumor prosthesis: soft-tissue failure ranged from 0% to 31%
(overall: 1.2%), aseptic loosening ranged from 0% to 11% (overall: 2.8%), structural failure ranged from 0% to 19% (overall: 2.2%), infection ranged from 0% to 13% (overall: 2.1%), and tumor recurrence/progression ranged from 0% to 11% (overall: 2.0%). Five-, ten-, and twenty-year implant survival for tumor prostheses ranged from 63% to 100% (12 studies), 55% to 86% (7 studies), and 56% to 57% (2 studies) ( Table 3) .
Overall revision rate ranged from 0% to 38% in allograft-prosthesis composites (overall: 19%) ( Table 2) . Reasons for implant failure after reconstruction with an allograft-prosthesis composite: soft-tissue failure was 0% (overall: 0%), aseptic loosening ranged from 0% to 19% (overall:
2.3%), structural failure ranged from 0% to 27% (overall: 8.3%), infection ranged from 0% to 19% (overall: 6.5%), and tumor recurrence/ progression ranged from 0% to 5% (overall: 1.9%). Five-and ten-year implant survival for allograft-prosthesis composites ranged from 84% to 100% (four studies), and 81% to 86% (four studies) ( Table 3) . No 20-year survival was reported for allograft-prosthesis composites.
| Limb salvage rate and reasons for amputation
Overall limb salvage rate ranged from 76% to 100% in tumor prostheses (overall: 97%), and from 94% to 100% in allograftprosthesis composites (overall: 99%) ( Table 2) 
| Functional outcome
Average MSTS score for tumor prostheses ranged from 56% to 94% (17 studies), and from 58% to 93% for allograft-prosthesis composites (7 studies) ( Table 4 ).
| Additional outcomes
We found an overall, irrespective of type of reconstruction, dislocation rate of 5.1% (range among studies: 0%-29%) (Appendix 3); 3.4% for hemiarthroplasties (range among studies: 0%-20%), and 10% for reconstructions with an acetabular component (range among studies:
0%-100%).
| DISCUSSION
Many studies have described outcomes after proximal femoral tumor resection followed by tumor prosthesis or allograft-prosthesis composite reconstruction. However, most studies are relatively small. We therefore aimed to provide an overview and summarize all studies reporting on outcomes after endoprosthetic reconstruction of proximal femoral tumors. We found that overall revision rates are high and that modes of failure seem to differ between tumor prostheses and allograftprosthesis composites (Table 5) . Limb salvage rate is high, despite high revision rates, and seems to be comparable between tumor prostheses and allograft-prosthesis composites. Functional outcome was reasonable to good on average for both treatment modalities, but function varies substantially among and within studies (Table 5 ).
This study has limitations. First, indications for both surgical modalities differed, patients who had a reconstruction with an allograft-prosthesis composite were younger on average and more often had a primary bone malignancy as compared with those who underwent reconstruction with a tumor prosthesis. We see this confounding by indication bias as an important limitation as this might have influenced outcomes. However, it was unfortunately not possible to report outcomes for primary bone tumors separately (eg, excluding secondary tumors and hematological malignancies) as outcomes were often lumped together. Second, the type of implant used, surgical technique (eg, use of cement, approach), experience of the surgeon, and postoperative rehabilitation undoubtedly differed between and within studies. We see this as an important limitation as we were not able to stratify for this. We reported those surgical characteristics that were most frequently described in included studies. We found about three times more studies and patients who underwent proximal femoral reconstruction for tumor than Thampabillary et al 4 We feel that separately reporting results for tumor prostheses and allograft-prosthesis composites, and using the definition and types of implant failure as described by Henderson further strengthens our study. 18 We separately reported outcomes for tumor prostheses and allograft-prosthesis composites as we felt that these techniques are substantially different. However, one should acknowledge the limitations and relatively low quality of the included studies and should be careful with directly comparing the results of these techniques and drawing firm conclusions. The lower soft-tissue failure rate (ie instability and tendon rupture 18 ) for allograft-prosthesis composite versus tumor prostheses might be explained by allowing better reconstruction of soft-tissue, including reattachment of the abductor mechanism. 2,27,52 Preservation of the acetabulum, repair of the joint capsule, and reconstruction of the abductor mechanism are important aspects of restoring joint stability and avoiding dislocation. 27 The higher rate of structural failure requiring revision in the allograft-prosthesis composite group is predominantly caused by allograft fracture, allograft resorption, and allograft-host bone nonunion. 2, 47, 48, [50] [51] [52] Overall failure rate for structural allografts reported in the literature are substantial, ranging from 10% to 50%. [55] [56] [57] The most common reasons for allograft failure reported in a study specifically looking at allografts (n = 945) were failure of graft incorporation, graft fracture, graft resorption, and infection, this is in line with our findings in this systematic review. 55 Immunological interaction and biomechanical properties are thought to play a role in allograft incorporation, but the mechanisms of failure remain incompletely understood. [56] [57] [58] This, might also partially explain the higher infection rate in allograft-prosthesis composites as compared with reconstruction with a tumor prosthesis. In addition, differences in adhesiveness for bacteria on tumor prosthesis versus allograft might play a role. We feel that the comparable revision T A B L E 5 Summarized results Despite high overall revision rates, most studies demonstrate high limb salvage rates with only few patients eventually requiring amputation, mostly for oncological reasons. Despite this, the low risk of future amputation, as presented in this review, needs to be discussed with the patient.
Reasons
Functional outcome was reasonable to good on average and overlapped for both reconstruction methods. The substantial variation between studies might be explained by differences in follow-up. Future studies assessing physical function should focus on using patient reported outcome measures, preferably with a preoperative and postoperative survey, as clinician based surveys are often biased. 53, 54, 59, 60 In conclusion, overall revision rates are high after both tumor prostheses and allograft-prosthesis composite reconstructions. Reasons for failure seem to differ between both groups and implant survival decreases steadily with time in both groups. Rate and reasons for amputation are comparable between tumor prostheses and allograft-prosthesis composites. Functional outcome was reasonable to good on average for both treatment modalities.
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